Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
Coverage (18)
- Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal Reuters · 45d ago
- ATAI Stock Soars On Eli Lilly’s $2.8B Buyout Yahoo Finance · 45d ago broke it first
- Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion WSJ · 45d ago
- Eli Lilly buys psychedelic biotech backed by Peter Thiel Financial Times · 45d ago
- Eli Lilly agrees to $3.8B psychedelic buy Axios · 45d ago
- ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly Yahoo Finance · 45d ago broke it first
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PR Newswire · 45d ago
- Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction CNBC · 45d ago
- This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks Barron's · 45d ago
- Why Is ATAI Stock Soaring 59% After-Hours? TradingView · 45d ago
- Psychedelic drugmaker AtaiBeckley shares soar 66% on Eli Lilly buyout talks (LLY:NYSE) Seeking Alpha · 45d ago
- Here Is Why AtaiBeckley (ATAI) Is One Of The 10 Best Stocks Under $10 That Could Triple Yahoo Finance · 45d ago broke it first
- Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports Reuters · 45d ago
- Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley Bloomberg.com · 45d ago
- Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion Psychedelic Alpha · 45d ago
- Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy Yahoo Finance · 45d ago broke it first
- Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion Bloomberg.com · 45d ago
- Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion Yahoo Finance · 45d ago broke it first
What happened
Eli Lilly is in discussions to acquire AtaiBeckley, a company focused on the development of psychedelic drugs. Following reports of these negotiations, AtaiBeckley shares experienced substantial growth in after-hours trading.
Coverage from Bloomberg News, Reuters, TradingView, Seeking Alpha, and Yahoo Finance highlights the market reaction, noting significant increases in stock value. Analysts and financial reports have identified the company as a notable stock under $10.
Future developments depend on whether the reported buyout discussions result in a finalized agreement. Coverage does not yet specify the terms of any potential deal or the timeline for a formal announcement.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 45d ago.
Questions people are asking
What is driving the movement in AtaiBeckley stock?
The increase in share price is linked to reports regarding potential buyout discussions with Eli Lilly.
Has a deal between Eli Lilly and AtaiBeckley been finalized?
No. Coverage indicates that Eli Lilly is currently nearing a deal, but reports do not confirm a final agreement.
How much has AtaiBeckley's stock risen?
Market reports indicate stock increases ranging between 59% and 66% during after-hours trading.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
Hugging Face has been fielding M&A interest for a deal worth at least $13 billion
AI platform Hugging Face is exploring a sale valuing the company at $13 billion.
Stock Market Today: Dow Opens Higher, Bond Yields Dive After Treasury Steps Up Buybacks
The Treasury Department doubled its debt buybacks, driving US bond yields lower and prompting a market rally.
Target is set to report earnings before the bell. Here's what to expect
Target prepares to report its second-quarter earnings before the opening bell.
Chinese Robot Maker Unitree Soars 500 Percent in Trading Debut
Chinese humanoid robot maker Unitree surges in its stock market debut, recording massive gains in trading.
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.